Encompass Health (EHC) Stock Forecast & Price Target

Compare

433 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EHC Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Encompass

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EHC Stock 12 Month Forecast

Average Price Target

$142.80

▲(32.17% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $142.80 with a high forecast of $150.00 and a low forecast of $134.00. The average price target represents a 32.17% change from the last price of $108.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"90":"$90","151":"$151","105.25":"$105.3","120.5":"$120.5","135.75":"$135.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$142.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$134.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[90,105.25,120.5,135.75,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.7,117.41538461538462,120.13076923076923,122.84615384615385,125.56153846153846,128.27692307692308,130.9923076923077,133.7076923076923,136.42307692307693,139.13846153846154,141.85384615384615,144.56923076923076,147.2846153846154,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.7,116.86153846153846,119.02307692307693,121.18461538461538,123.34615384615385,125.50769230769231,127.66923076923078,129.83076923076925,131.9923076923077,134.15384615384616,136.31538461538463,138.4769230769231,140.63846153846154,{"y":142.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.7,116.18461538461538,117.66923076923077,119.15384615384616,120.63846153846154,122.12307692307692,123.6076923076923,125.0923076923077,126.57692307692308,128.06153846153848,129.54615384615386,131.03076923076924,132.51538461538462,{"y":134,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":98.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$150.00

Average Price Target$142.80

Lowest Price Target$134.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanna Gajuk

Bank of America Securities

―

Buy

―

Reiterated

12/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (NASDAQ: PTCT), ALX Oncology Holdings (NASDAQ: ALXO) and Encompass Health (NYSE: EHC)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/03/25

Encompass Health (EHC) Gets a Buy from William Blair

David S Macdonald

Truist Financial

$140

Buy

29.58%

Upside

Reiterated

10/31/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (NASDAQ: ARQT), Encompass Health (NYSE: EHC) and Glaukos (NYSE: GKOS)

Matthew Gillmor CFA

KeyBanc

$140

Buy

29.58%

Upside

Reiterated

10/31/25

KeyBanc Sticks to Its Buy Rating for Encompass Health (EHC)

Andrew Mok CFA

Barclays

$141→$150

Buy

38.84%

Upside

Reiterated

10/30/25

Encompass Health price target raised to $150 from $141 at BarclaysEncompass Health price target raised to $150 from $141 at Barclays

A.J. Rice

UBS

$140→$150

Buy

38.84%

Upside

Reiterated

10/02/25

Encompass Health price target raised to $150 from $140 at UBSEncompass Health price target raised to $150 from $140 at UBS

Ann Hynes

Mizuho Securities

$134

Buy

24.03%

Upside

Reiterated

09/16/25

Encompass Health (EHC) Receives a Buy from Mizuho Securitieswe reiterate our Outperform rating and our price target of $134.

Whit Mayo

Leerink Partners

$130→$134

Buy

24.03%

Upside

Reiterated

08/06/25

Encompass Health: Strong Financial Performance and Growth Potential Drive Buy Rating

Brian Tanquilut

Jefferies

$130

Buy

20.33%

Upside

Reiterated

07/21/25

Jefferies Sticks to Their Buy Rating for Encompass Health (EHC)

John Ransom

Raymond James

$120→$130

Buy

20.33%

Upside

Reiterated

04/28/25

Analysts' Top Healthcare Picks: Encompass Health (EHC), Evaxion Biotech (EVAX)

Ben Hendrix

RBC Capital

$110→$125

Buy

15.70%

Upside

Reiterated

04/27/25

RBC Capital Reaffirms Their Buy Rating on Encompass Health (EHC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanna Gajuk

Bank of America Securities

―

Buy

―

Reiterated

12/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (NASDAQ: PTCT), ALX Oncology Holdings (NASDAQ: ALXO) and Encompass Health (NYSE: EHC)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/03/25

Encompass Health (EHC) Gets a Buy from William Blair

David S Macdonald

Truist Financial

$140

Buy

29.58%

Upside

Reiterated

10/31/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (NASDAQ: ARQT), Encompass Health (NYSE: EHC) and Glaukos (NYSE: GKOS)

Matthew Gillmor CFA

KeyBanc

$140

Buy

29.58%

Upside

Reiterated

10/31/25

KeyBanc Sticks to Its Buy Rating for Encompass Health (EHC)

Andrew Mok CFA

Barclays

$141→$150

Buy

38.84%

Upside

Reiterated

10/30/25

Encompass Health price target raised to $150 from $141 at BarclaysEncompass Health price target raised to $150 from $141 at Barclays

A.J. Rice

UBS

$140→$150

Buy

38.84%

Upside

Reiterated

10/02/25

Encompass Health price target raised to $150 from $140 at UBSEncompass Health price target raised to $150 from $140 at UBS

Ann Hynes

Mizuho Securities

$134

Buy

24.03%

Upside

Reiterated

09/16/25

Encompass Health (EHC) Receives a Buy from Mizuho Securitieswe reiterate our Outperform rating and our price target of $134.

Whit Mayo

Leerink Partners

$130→$134

Buy

24.03%

Upside

Reiterated

08/06/25

Encompass Health: Strong Financial Performance and Growth Potential Drive Buy Rating

Brian Tanquilut

Jefferies

$130

Buy

20.33%

Upside

Reiterated

07/21/25

Jefferies Sticks to Their Buy Rating for Encompass Health (EHC)

John Ransom

Raymond James

$120→$130

Buy

20.33%

Upside

Reiterated

04/28/25

Analysts' Top Healthcare Picks: Encompass Health (EHC), Evaxion Biotech (EVAX)

Ben Hendrix

RBC Capital

$110→$125

Buy

15.70%

Upside

Reiterated

04/27/25

RBC Capital Reaffirms Their Buy Rating on Encompass Health (EHC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Encompass Health

1 Month

xxx

Success Rate

18/28 ratings generated profit

Average Return

+2.09%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +2.09% per trade.

3 Months

xxx

Success Rate

25/31 ratings generated profit

Average Return

+6.37%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.65% of your transactions generating a profit, with an average return of +6.37% per trade.

1 Year

David S MacdonaldTruist Financial

Success Rate

23/28 ratings generated profit

Average Return

+27.24%

reiterated a buy rating last month

Copying David S Macdonald's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +27.24% per trade.

2 Years

xxx

Success Rate

27/31 ratings generated profit

Average Return

+38.65%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +38.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EHC Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EHC has received 8 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. EHC average Analyst price target in the past 3 months is 142.80.

Each month's total comprises the sum of three months' worth of ratings.

EHC Financial Forecast

EHC Earnings Forecast

Next quarter’s earnings estimate for EHC is $1.30 with a range of $1.23 to $1.35. The previous quarter’s EPS was $1.23. EHC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.

EHC Sales Forecast

Next quarter’s sales forecast for EHC is $1.54B with a range of $1.53B to $1.55B. The previous quarter’s sales results were $1.48B. EHC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EHC has Performed in-line its overall industry.

EHC Stock Forecast FAQ

What is EHC’s average 12-month price target, according to analysts?

Based on analyst ratings, Encompass Health’s 12-month average price target is 142.80.

What is EHC’s upside potential, based on the analysts’ average price target?

Encompass Health has 32.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EHC a Buy, Sell or Hold?

Encompass Health has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Encompass Health’s price target?

The average price target for Encompass Health is 142.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $134.00. The average price target represents 32.17% Increase from the current price of $108.04.

What do analysts say about Encompass Health?

Encompass Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of EHC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Encompass Health (EHC) Stock Forecast & Price Target

EHC Analyst Ratings

EHC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Encompass Health

EHC Analyst Recommendation Trends

EHC Financial Forecast

EHC Earnings Forecast

EHC Sales Forecast

EHC Stock Forecast FAQ

Detailed List of Analyst Forecasts